Targeting prandial hyperglycemia: how important is it and how best to do this?
The contribution of postprandial glucose (PPG) excursions to the overall hyperglycemia of patients with type 2 diabetes depends on the degree of diabetic control. PPG is a major contributor in patients with hemoglobin A(1c) (HbA(1c)) levels below 7.3%, whereas the contribution of fasting plasma glucose (FPG) is preponderant in poorly controlled patients. In addition, the loss of postprandial glycemic control precedes stepwise degradation of fasting with worsening diabetes. As a consequence, monitoring after meals is particularly important in patients with HbA(1c) levels ranging from 6.5% to 8%. In such patients, targeting PPG below 140 mg/dL should be one of the main objectives to achieve HbA(1c) less than 6.5%. The new hypoglycemic agents, such as the glucagon-like peptide-1 analogues and the dipeptidyl peptidase-4 inhibitors which have a gluco-dependent insulinotropic effect, should normally reinforce our therapeutic armamentarium for achieving the glycemic targets that should include the three components of the glucose triad: HbA(1c), FPG, and PPG.
Monnier
Louis
L
Laboratory of Human Nutrition, University Institute of Clinical Research, 641 Avenue du Doyen Giraud, 34093 Montpellier Cedex 5, France. louis.monnier@inserm.fr
Colette
Claude
C
D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy / Q000503:physiopathology*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D019518:Postprandial Period / Q000502:physiology*
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human
N Engl J Med. 1993 Sep 30;329(14):977-86
8366922
JAMA. 2003 Jul 23;290(4):486-94
12876091
Diabetes Metab. 2004 Apr;30(2):113-9
15223983
Eur J Clin Invest. 2000 Aug;30 Suppl 2:3-11
10975048
N Engl J Med. 2007 Feb 1;356(5):437-40
17267901
Int J Clin Pharmacol Ther. 2003 Oct;41(10):421-40
14703948
Endocr Pract. 2006 Jan-Feb;12 Suppl 1:6-12
16627372
Diabetes Care. 2003 Jan;26 Suppl 1:S5-20
12502614
Diabetes Care. 2007 Feb;30(2):263-9
17259492
Diabet Med. 1998 Apr;15(4):290-6
9585393
N Engl J Med. 1988 May 12;318(19):1231-9
3283554
Diabetes. 1996 Aug;45(8):1044-50
8690150
Diabetes Metab. 2006 Sep;32 Spec No2:2S11-6
17375401
N Engl J Med. 1992 Sep 3;327(10):707-13
1495524
Diabetes Care. 2002 Apr;25(4):737-41
11919134
Diabetes Care. 1997 Dec;20(12):1822-6
9405900
Arch Intern Med. 2004 Oct 25;164(19):2090-5
15505121
Diabetes. 2008 Apr;57(4):995-1001
18223010
Diabetologia. 2006 May;49(5):846-54
16532323
Drugs. 2001;61(11):1625-60
11577798
Diabetologia. 1995 Dec;38(12):1378-88
8786010
Lancet. 1999 Aug 21;354(9179):617-21
10466661
Nature. 2001 Dec 13;414(6865):813-20
11742414
Diabetes Care. 2008 Feb;31 Suppl 2:S150-4
18227477
Circulation. 2004 Jul 13;110(2):214-9
15197140
Diabetes Care. 2002 Feb;25(2):275-8
11815495
Stroke. 2004 May;35(5):1073-8
15073402
N Engl J Med. 2005 Jan 13;352(2):174-83
15647580
N Engl J Med. 1984 Mar 22;310(12):746-50
6366551
Diabetes Care. 2003 Mar;26(3):881-5
12610053
Horm Metab Res. 2007 Sep;39(9):683-6
17846977
Diabetes Care. 2001 Dec;24(12):2023-9
11723077
Diabetes Metab. 2008 Jun;34(3):207-16
18511324
Diabetes. 2005 Jan;54(1):1-7
15616004
Diabetes. 1988 Jun;37(6):667-87
3289989
Diabetologia. 2001 Dec;44(12):2107-14
11793012
Diabetes. 1995 Nov;44(11):1249-58
7589820
BMJ. 2000 Aug 12;321(7258):405-12
10938048
Diabetes Care. 2006 Aug;29(8):1963-72
16873813
Diabetes Care. 1999 Feb;22(2):233-40
10333939
Diabetologia. 1996 Dec;39(12):1577-83
8960845
Eur J Clin Invest. 2006 Apr;36(4):231-5
16620284
J Clin Endocrinol Metab. 2006 Mar;91(3):813-9
16352690